Low-cap oncology stocks: Small companies fighting cancer
As knowledge of what causes and helps prevent cancer develops, so does the expertise on how to tackle it face-on. Today, oncology represents one of the world’s fastest-moving therapeutic areas, set to represent more than a quarter of pharmaceutical sales by 2022. Part of this growth has been facilitated by the emergence of smaller companies taking innovative and novel approaches to the clinical practices such as T-cell treatments and precision medicines.
This Spark contains some of these smaller firms involved in cancer research or treatment in the US, with a market cap of less than $300m. For bigger companies, we have you covered with major firms or mid-cap firms. But don't rely on these lists alone. This isn't advice, so make sure you do your own research.